Solutions and early-detection assays for labs of all sizes
In the global fight against neurodegenerative diseases, we're with you every step of the way.
Neurodegenerative disease by the numbers
- 153 million people worldwide are projected to have dementia by 2050.
- Over 8.5 million people currently have Parkinson's disease, with around 2.1 million cases of Parkinsonian dementia.
- 27-60 million people sustain a traumatic brain injury each year.
- 1.8 million people are affected by multiple sclerosis.
New high-quality blood-based assays let laboratories detect Alzheimer's disease early, in a less invasive way.
New blood tests aim to detect Alzheimer's less invasively and more accessibly. Labs could soon play a leading role in Alzheimer's testing. Rather than relying on invasive, often hard-to-access methods such as CSF testing and PET scans, the future of Alzheimer's testing could center on the lab, with several new blood tests targeting Alzheimer's biomarkers.
Early diagnosis and intervention can improve outcomes for people living with Alzheimer's disease and for their caregivers and families. Today, Alzheimer's is diagnosed through symptom reporting, cognitive testing and lab tests that rule out reversible or treatable causes of cognitive change. Imaging such as CT, MRI and PET scans may also be used. However, brain changes can occur long before clinical symptoms appear, making early diagnosis particularly challenging. Alzheimer's progresses across three phases — preclinical, mild cognitive impairment, and dementia (further split into mild, moderate and severe). Progression varies and is influenced by age, environment, genetics and sex. Detecting amyloid pathology — a hallmark of Alzheimer's — earlier and more accurately is a significant step forward.
BECKMAN COULTER INTRODUCES NEW
Blood-based Neurology Disease Assays (for Research Use Only)
p-Tau217 I GFAP I NfL I NEW APOE ε4 Assays
And a NEW Fully Automated APOE ε4 Test > Read the study
The APOE (Apolipoprotein E) gene is a key genetic factor in Alzheimer's disease (AD); its ε4 allele is the strongest known genetic risk factor for AD. APOE is involved in lipid metabolism and plays a crucial role in clearing β-amyloid (Aβ), the protein that forms plaques in the brains of AD patients. The ε4 allele is associated with a higher risk of amyloid accumulation, neuroinflammation and tau pathology, which together contribute to neurodegeneration. The relationship between APOE and AD remains an active research area as scientists work to understand the mechanisms and develop personalized prevention and treatment.
This new Beckman Coulter APOE ε4 RUO blood-based immunoassay offers over 99% concordance with PCR genotyping — in only 20 minutes. Although not diagnostic, APOE ε4 status can provide insight into the risk of developing Alzheimer's disease.
- Read the study: scientists determined the sensitivity, imprecision and concordance with PCR of a new APOE ε4 zygosity RUO assay on the Beckman Coulter DxI 9000 and Access 2 Immunoassay Analyzers.
- White Paper: The Role of APOE in Alzheimer's Disease: Genetic Variants, Mechanisms and Therapeutic Implications, by Kinal Bhatt, MD, MPH.
These neurogenerative RUO assays are all immediately available on the DxI 9000 Immunoassay Analyzer
RUO Assays in Development :
ß-AmyIoid 1-42 I BD Tau I
MTBR-Tau I
TDP-43
NEW APOE ε4 Assays Blood-based Neurology Disease Assays
Access APOE ε 4 (RUO) assay (REF D16691) for the Access 2 Immunoassay System and the DxI 9000 Immunoassay Analyzer
Information Bulletin
p-Tau217 Blood-based Neurology Disease Assays
Access p-Tau217 (RUO) assay (REF D14230) for the DxI 9000 Immunoassay Analyzer
GFAP Assays Blood-based Neurology Disease Assays
Access GFAP (RUO) assay (REF D11672) for the Access 2 Immunoassay System and the DxI 9000 Immunoassay Analyzer
Information Bulletin
NfL Assays Blood-based Neurology Disease Assays
Access NfL (RUO) assay (REF D15673) for the Access 2 Immunoassay
System and the DxI 9000 Immunoassay Analyzer
Information Bulletin
Neurology blood tests improve diagnosis and management of patients in Alzheimer's and beyond
Beckman Coulter Life Sciences and T-NeuroDx collaborate on early Alzheimer's diagnostics
The collaboration combines T-NeuroDx's research in Alzheimer's diagnostics with Beckman Coulter's flow cytometry products. It aims to demonstrate the test's potential to detect an initiating event before dysregulated beta-amyloid and tau — the current standard of care for Alzheimer's biomarker-based diagnostics — become detectable, the company said in a statement.
"The neuroimmunology field has long been complex, which has stood in the way of major advances; streamlined flow cytometry assays could offer promising new potential for translational research," said Jean-Marc Busnel, Senior Staff Research Scientist.
WHITE PAPER
Alzheimer’s disease:
Challenges to diagnosis
and the emerging treatment landscape
WHITE PAPER
The Role of APOE in Alzheimer's Disease: Genetic Variants, Mechanisms, and Therapeutic Implications
STUDY
High-throughput, fully automated immunoasday for detecting APOE ε4 zygosity in EDTA plasma:
scientists determined the sensitivity, imprecision and PCR concordance of a new APOE ε4 zygosity RUO assay.
WHITE PAPER
Blood-Based Biomarkers and the Future of Alzheimer’s Disease Diagnostics
Why blood-based biomarkers for Alzheimer’s disease?
How do blood-based biomarkers for Alzheimer’s disease work?